command

BREAKING NEWS: New Clinical Trial Opening

PRESS RELEASE
Contact Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com
CAMBRIDGE, MA – Sep. 10, 2013 – Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the initiation of COMMAND (Control Of Mesothelioma with MAiNtenance Defactinib). COMMAND is a registration-directed trial of lead cancer stem cell inhibitor […]